The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...

Welcome to the NovoCure Q3 2024 earnings conference call. [Operator instructions] Please be advised that today's conference ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial ...

Q3 2024 Earnings Call Transcript October 30, 2024 NovoCure Limited beats earnings expectations. Reported EPS is $-0.28, expectations were $-0.34. Operator: Good day, and thank you for standing by.

The data was still under wraps at that time, but has just been revealed in the ESMO congress abstract drop – a 3.2 month improvement over control, compared to 1.6 months at ASCO. Taken in ...

Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...

‘With the ESMO and ASCO guidelines recommending ESR1 testing alongside aromatise inhibitor treatment, detecting ESR1 mutations has become increasingly important for clinicians and scientists. We are ...

The results from the Checkmate 067 trial, presented today (Sunday 15 September) at the 2024 ESMO Annual Meeting in Barcelona, Spain, and simultaneously published in The New England Journal of Medicine ...

Possible solutions to address these resource barriers include investment in human resources by increasing recruitment and training of the workforce, engagement of medical trainees and patients in ...